Autoimmune Diseases and Conditions – Psoriatic Arthritis – InsuranceNewsNet


Health Policy and Law Daily

2022 JUNE 02 (NewsRx) — By a News reporter staff news editor at Health Policy and Law Daily — Recent study results on psoriatic arthritis have been published. According to news coverage Boston, Mass, from NewsRx editors, the research states: “Specialty drugs offer effective treatment with limited side effects for patients with psoriasis and psoriatic arthritis; However, variable coverage and high costs often pose an obstacle to treatment for patients with statutory health insurance.”

The news journalists received a quote from the research of Tufts Medical Center: “Our aim was to assess the coverage of specialty medications for psoriasis and psoriatic arthritis by commercial insurance companies. We compiled data on specialty drug coverage for psoriasis and psoriatic arthritis using the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database and analyzed the data for notable trends. The SPEC database lists coverage decisions for 158 specialty drugs from 17 of the largest commercial health plans in the US, along with data on the types of evidence used by those plans in making coverage decisions. Our results showed that insurance plans tend to be more restrictive than those US Food and Drug Association (FDA) label when it comes to drugs for psoriasis and psoriatic arthritis. Additionally, drugs for psoriatic arthritis tended to be less restricted than for psoriasis, and drugs were most often approved as second-line drugs for both indications.”

According to the news reporters, the study concluded, “Our analysis confirms that there are differences in insurance coverage for the indications psoriasis and psoriatic arthritis.”

For more information on this research, see: Commercial Insurance Company Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis2022. The publisher for Journal of Psoriasis and Psoriatic Arthritis is SAGE Publications.

A free version of this journal article is available at https://doi.org/10.1177/24755303221101843.

Our news editors report that additional information can be obtained by contacting us Christina learned, Department of Dermatology, Tufts Medical Center, Boston, MA, United States. Additional authors of this study are Sara Alsukait, Kristin R Fiumara, Melissa OrtegaJames D Chambers, David Rosemary.

ORCID is an identifier for authors and contains bibliographic information. The following is ORCID information for the author of this study: David Rosemary (http://orcid.org/0000-0003-2786-0708).

(Our reports provide fact-based news about research and discoveries from around the world.)

Comments are closed.